Coexpression of p21WAF1/CIP1 in adenovirus vector transfected human primary hepatocytes prevents apoptosis resulting in improved transgene expression

Gene Therapy

Volumn 10, Issue 8, 2003, Pages 668-677

  Wolff, G ^a,b   Schumacher, A ^a   Nuessler, A K ^a   Ruppert, V ^a   Karawajew, L ^a   Wehnes, E ^a   Neuhaus, P ^a   Dorken B ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Apoptosis; Cell cycle; Gene therapy; p21

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; COMPLEMENTARY DNA; LACTATE DEHYDROGENASE; PENICILLIN G; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; STREPTOMYCIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER; LIVER CELL; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; MICE; MICE, MUTANT STRAINS; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0038404794     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301864     Document Type: Article

References (50)

1. Strauss M. Liver-directed gene therapy: prospects and problems. Gene Ther 1994; 1: 156-164.
2. Ilan Y, Saito H, Thummala NR, Chowdhury NR. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis 1999; 19: 49-59.
3. Smith TA et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
4. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
5. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
6. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996; 3: 412-420.
7. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-144.
8. Armentano D et al. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J Virol 1999; 73: 7031-7034.
9. Gorziglia MI et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol 1999; 73: 6048-6055.
10. Wersto RP et al. Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J Virol 1998; 72: 9491-9502.
11. Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol 1997; 71: 1739-1746.
12. Bilbao G et al. Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene. J Virol 1999; 73: 6992-7000.
13. Gartel AL, Tyner AL. The growth-regulatory role of p21 (WAF1/CIP1). In: Maciera-Coelhos A (ed). Progress in Molecular and Subcellular Biology, Vol 1. Springer: Berlin, Heidelberg, 1998, pp 43-71.
14. Niculescu A et al. Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18: 629-643.
15. Medema RH, Klompmarker R, Smits VA, Rijksen G. p21 waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998; 16: 431-441.
16. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced b anticancer agents in cells lacking p21. Nature 1996; 381: 713-716.
17. Lukas J et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 1997; 11: 1479-1492.
18. Sandig V et al. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3: 313-319.
19. Brand K et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 1998; 5: 1363-1371.
20. Wolff G et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-629.
21. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
22. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
23. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
24. Waldman T et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3: 1034-1036.
25. Mantel C et al. p21 (cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 1999; 93: 1390-1398.
26. Tsao YP et al. Adenovirus-mediated p21 (WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 1999; 73: 4983-4990.
27. Katayose D, Wersto R, Cowan KH, Seth P. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ 1995; 6: 1207-1212.
28. Chen J et al. Effects of ectopic overexpression of p21 (WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 1996; 13: 1395-1403.
29. Fussenegger M et al. Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. Nat Biotechnol 1998; 16: 468-472.
30. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
31. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
32. Castell JV et al. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther 1997; 4: 455-464.
33. Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
34. Worgall S et al. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8: 1675-1684.
35. Worgall S, Wolff G, Falck PE, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
36. Lieber A et al. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol 1998; 72: 9267-9277.
37. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
38. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995; 1: 890-893.
39. Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
40. Smith TA et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
41. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-6377.
42. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
43. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389: 239-242.
44. Nüssler AK et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992; 176: 261-264.
45. Dorko K et al. A new technique for isolating and culturing human hepatocytes from whole or split livers not used for transplantation. Cell Transplant 1994; 3: 387-395.
46. Wolff G et al. Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulated organ function to regulate blood glucose by TRH. Nat Genet 1996; 12: 274-279.
47. Zhang WW et al. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993; 15: 868-872.
48. Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antotrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
49. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
50. Wolff G et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997, 71: 624-629.